← ANALYST RATINGS · TIPRANKS
Cabaletta Bio (CABA): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $20.67, the highest $30.00, the lowest $16.00. The average is +1,365.7% from the last price of $1.41.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 | Hold | +41.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 | Hold | +41.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 | Hold | +41.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 | Hold | +41.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 | Hold | +41.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Hold | +41.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $16.00 | Buy | +1,034.8% | Reiterated | 21.09.26on TipRanks 13:55 | −5.1%next day +1.6% · 5 days −17.7% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 02.09.26on TipRanks 11:10 | +7.7%next day −3.6% · 5 days −22.3% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $10.00 | Buy | +609.2% | Reiterated | 01.09.26on TipRanks Sep 2 07:05 | +6.8%next day +7.7% · 5 days −11.9% | ↗ |
| Unknown Analyst | Wells Fargo | $3.00 | Hold | +112.8% | Assigned | 01.09.26on TipRanks Sep 2 03:35 | +6.8%next day +7.7% · 5 days −11.9% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $13.00 | Buy | +822.0% | Assigned | 17.08.26on TipRanks Aug 14 08:35 | +1.7%next day +5.6% · 5 days +15.2% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $30.00 | Buy | +2,027.7% | Reiterated | 14.08.26on TipRanks 08:55 | +1.7%next day +5.6% · 5 days +15.2% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $16.00 | Buy | +1,034.8% | Reiterated | 13.08.26on TipRanks Aug 14 08:15 | −5.6%next day +1.7% · 5 days +19.7% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 13.08.26on TipRanks 12:55 | −5.6%next day +1.7% · 5 days +19.7% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $14.00 | Buy | +892.9% | Reiterated | 23.03.26on TipRanks 09:45 | −5.1%next day −5.0% · 5 days −8.8% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $4.00 | Hold | +183.7% | Reiterated | 17.12.25on TipRanks Dec 18 06:50 | −1.4%next day +2.7% · 5 days −9.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Cabaletta Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.67 at a price of $1.92 (+663.9%); now: $14.67 at $1.41 (+940.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 6 | 4 | 4 | 4 |
| Buy | 6 | 7 | 5 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.32 (from $-0.35 to $-0.24). Last quarter: $-0.34.
Best top-analyst consensus in the sector · Healthcare
About Cabaletta Bio
- CEO: Steven A. Nichtberger
- Employees: 156
- 2929 Arch Street, Philadelphia, PA, 19104, US
- www.cabalettabio.com
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗